Health & Medical · Week of Nov 9, 2026
Aflac, PAVmed, CLEAR report results and launches: health releases
PAVmed, Zhengye Biotechnology, Meridian Health Plan of Illinois and IceCure also reported; releases centered on financial results and partnerships.
Financial updates led the week. Zhengye Biotechnology Holding Limited reported lower six-month revenue and a narrower net loss, PAVmed reported preliminary third-quarter results alongside the start of Medicare payments for Lucid Diagnostics' EsoGuard test, and Aflac Incorporated raised its quarterly dividend by 4.9%.
Partnerships were the other common thread. Meridian Health Plan of Illinois committed $1,185,000 to March of Dimes for maternal and infant care in Chicagoland, and NAMSA formalised a preferred partnership with Advanced Medical Solutions. CLEAR launched two Epic integrations for identity verification, IceCure Medical added a patent in China, and Biomolecular Life Holdings agreed to a related-party land purchase in Colombia.
Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
Zhengye Biotechnology Holding Limited reported net revenue of RMB50.9 million for the six months ended June 30, 2026, down 18.3% from RMB62.3 million, with net loss narrowing to RMB22.2 million from RMB25.6 million. The veterinary vaccine maker attributes the revenue decline to customer cost-cutting, and its cash fell to RMB31.9 million from RMB50.3 million at the end of 2025.

PAVmed Inc.
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
PAVmed says its subsidiary Lucid Diagnostics began receiving Medicare payments for the EsoGuard Esophageal DNA Test in October, after performing 2,871 tests and recognizing $1.2 million in revenue in 3Q26. The company also says Veris Health started a 90-day GLP animal study ahead of a planned early 2027 FDA 510(k) submission, and reported cash and cash equivalents of $8.9 million, including $5.3 million of restricted cash.

Biomolecular Life Holdings, Inc.
Biomolecular Life Holdings, Inc. (BIOM) Agrees to Acquire Strategic Land in Llanogrande to Develop High-Tech Biomolecular Wellness and Longevity Retreat Near Medellín's International Airport
Biomolecular Life Holdings, Inc. agreed to acquire land in Llanogrande, Colombia, for a wellness spa and longevity retreat from BSD SAS, a company owned by CEO Jessika Wiesner, in an all-stock related-party deal. The share count will be set by independent appraisal, and the company targets opening in the first quarter of 2028, subject to financing, permitting and approvals.

CLEAR
CLEAR Offers Secure Identity in Epic for Community Provider Access and Controlled-Substance Prescribing
CLEAR says its CLEAR1 identity platform is live in two Epic Toolbox integrations, one letting community providers create EpicCare Link accounts with a selfie and government ID and one for electronic prescribing of controlled substances. The company says CLEAR1 has achieved Drummond Certified status, which it says confirms it meets applicable DEA requirements under 21 CFR Part 1311.

Aflac Incorporated
Aflac Incorporated Announces 4.9% Increase in the First Quarter 2027 Dividend
Aflac Incorporated declared a first quarter 2027 dividend of $0.64 per share, a 4.9% increase over the fourth quarter 2026 dividend, payable on March 1, 2027, to shareholders of record on February 17, 2027. Chairman and CEO Daniel P. Amos cited 44 consecutive years of dividend increases.

Meridian of Illinois
Meridian Health Plan of Illinois Announces Nearly $1.2M Partnership with March of Dimes for Local Maternal Healthcare Initiatives
Meridian Health Plan of Illinois, a Centene Corporation company, announced a $1,185,000 multiyear partnership with March of Dimes, with $1,100,000 going to the Mom & Baby Mobile Health Center program and a new unit set for early 2027. Remaining funds support community events, including one in Garfield Park on November 14, and March of Dimes reports that 1 in 12 Illinois babies were low birthweight in 2024.

IceCure Medical
IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
IceCure Medical says the China National Intellectual Property Administration granted it a patent covering a connector used in its cryogenic technology platform, bringing its portfolio to 42 patents. The grant follows the September 2026 approval from China's National Medical Products Administration to market ProSense and its cryoprobes in China.

NAMSA
NAMSA and Advanced Medical Solutions Announce Preferred Partnership
NAMSA and Advanced Medical Solutions entered a preferred partnership under which NAMSA will provide testing, biological safety, regulatory and clinical research services for AMS's surgical and wound care portfolio, including LIQUIBAND, RESORBA and ActivHeal. The companies say consolidating these services with one partner is designed to reduce handoffs and shorten the path from design to market.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Today Parents reporting.